Ciclesonide

DB01410

small molecule approved investigational

Deskripsi

Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

Struktur Molekul 2D

Berat 540.697
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) * 152 L/hr [Following IV administration of 800 mcg of ciclesonide]

Absorpsi

Ciclesonide and des-ciclesonide have negligible oral bioavailability (both less than 1%) due to low gastrointestinal absorption and high first-pass metabolism. The intranasal administration of ciclesonide at recommended doses results in negligible serum concentrations of ciclesonide.

Metabolisme

Des-ciclesonide undergoes metabolism in the liver to additional metabolites mainly by the cytochrome P450 (CYP) 3A4 isozyme and to a lesser extent by CYP 2D6.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1246 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Ciclesonide.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ciclesonide.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ciclesonide.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ciclesonide.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ciclesonide.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ciclesonide.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ciclesonide.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ciclesonide.
Pegaspargase The serum concentration of Ciclesonide can be increased when it is combined with Pegaspargase.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ciclesonide.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ciclesonide.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ciclesonide.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ciclesonide.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ciclesonide.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ciclesonide.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Ciclesonide.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ciclesonide.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Ciclesonide.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Ciclesonide.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ciclesonide.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ciclesonide.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Ciclesonide.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ciclesonide.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Ciclesonide.
Cladribine Ciclesonide may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Ciclesonide.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Ciclesonide.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Ciclesonide.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ciclesonide.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ciclesonide.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Ciclesonide.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Ciclesonide.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Ciclesonide.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Ciclesonide.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Ciclesonide.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ciclesonide.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ciclesonide.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Ciclesonide.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Ciclesonide.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Ciclesonide.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ciclesonide.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Ciclesonide.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Ciclesonide.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Ciclesonide.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ciclesonide.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Ciclesonide.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Ciclesonide.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ciclesonide.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ciclesonide.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Ciclesonide.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ciclesonide.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ciclesonide.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Ciclesonide.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Ciclesonide.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Ciclesonide.
Imatinib The serum concentration of Ciclesonide can be increased when it is combined with Imatinib.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Ciclesonide.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ciclesonide.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ciclesonide.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ciclesonide.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Ciclesonide.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Ciclesonide.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ciclesonide.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Ciclesonide.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Ciclesonide.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Ciclesonide.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Ciclesonide.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ciclesonide.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Ciclesonide.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Ciclesonide.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Ciclesonide.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ciclesonide.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ciclesonide.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Ciclesonide.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ciclesonide.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Ciclesonide.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Ciclesonide.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Ciclesonide.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Ciclesonide.
Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Ciclesonide.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Ciclesonide.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ciclesonide.
Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Ciclesonide.
Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Ciclesonide.
Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ciclesonide.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Ciclesonide.
Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Ciclesonide.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Ciclesonide.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Ciclesonide.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Ciclesonide.
Stepronin The risk or severity of adverse effects can be increased when Ciclesonide is combined with Stepronin.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Ciclesonide is combined with Hydroxychloroquine.
Castanospermine The risk or severity of adverse effects can be increased when Ciclesonide is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Ciclesonide is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Ciclesonide is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Ciclesonide is combined with Brequinar.
Ixabepilone The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ixabepilone.
Pirfenidone The risk or severity of adverse effects can be increased when Ciclesonide is combined with Pirfenidone.
Belinostat The risk or severity of adverse effects can be increased when Ciclesonide is combined with Belinostat.
Interferon alfa The risk or severity of adverse effects can be increased when Ciclesonide is combined with Interferon alfa.

Target Protein

Corticosteroid-binding globulin SERPINA6
Glucocorticoid receptor NR3C1

Referensi & Sumber

Synthesis reference: Beate Schmidt, "Process for preparing crystalline ciclesonide with defined particle size." U.S. Patent US20060128954, issued June 15, 2006.
Artikel (PubMed)
  • PMID: 17331475
    Mutch E, Nave R, McCracken N, Zech K, Williams FM: The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol. 2007 May 15;73(10):1657-64. Epub 2007 Jan 28.

Contoh Produk & Brand

Produk: 23 • International brands: 1
Produk
  • Alvesco
    Aerosol, metered • 80 ug/1 • Respiratory (inhalation) • US • Approved
  • Alvesco
    Aerosol, metered • 160 ug/1 • Respiratory (inhalation) • US • Approved
  • Alvesco
    Aerosol, metered • 80 ug/1 • Respiratory (inhalation) • US • Approved
  • Alvesco
    Aerosol, metered • 160 ug/1 • Respiratory (inhalation) • US • Approved
  • Alvesco
    Aerosol, metered • 80 ug/1 • Respiratory (inhalation) • US • Approved
  • Alvesco
    Aerosol, metered • 160 ug/1 • Respiratory (inhalation) • US • Approved
  • Alvesco
    Aerosol, metered • 50 mcg / act • Respiratory (inhalation) • Canada • Approved
  • Alvesco
    Aerosol, metered • 100 mcg / act • Respiratory (inhalation) • Canada • Approved
Menampilkan 8 dari 23 produk.
International Brands
  • Omniair

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul